Retinal Progenitor Cell Enrichment via Pax6D Reporter and WNT8B Silencing

Solution Overview

Problem

Current methods for producing retinal progenitor cells from human pluripotent stem cells result in a mixture of cell types, with less than 30% retinal cells and require manual selection, hindering large-scale, standardized production for disease modeling and cell therapies.

Innovation Solution

A method involving culturing human pluripotent stem cells in neural induction medium to form embryoid bodies, followed by retinal differentiation in a chemically defined medium, with the use of a Pax6D-reporter construct and WNT8B short hairpin interfering RNA to enrich for Pax6D-expressing retinal progenitor cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If current methods are used to produce retinal progenitor cells from human pluripotent stem cells, then cell production is achieved, but the purity is low (less than 30% retinal cells) and manual selection is required

Engineering Contradiction:
Core Design Contradiction:
Manufacturing precisionVSEase of operation

Solution Approach 1:

The patent uses a Pax6D-reporter construct that enables retinal progenitor cells to express a detectable reporter (such as fluorescent protein), creating a visual/color distinction between retinal cells and other cell types. This allows automated identification and sorting of pure retinal cell populations without manual selection, directly resolving the contradiction between purity and ease of operation

Inventive Principle:
Principle #32Color changes

Solution Approach 2:

The patent employs flow cytometry or similar automated sorting systems that detect reporter expression and sort cells based on this signal. This feedback mechanism automatically identifies and separates retinal progenitor cells from other cell types, eliminating manual selection while achieving high purity

Inventive Principle:
Principle #23Feedback

2Productivity

If current methods are used to produce retinal progenitor cells, then cell production is achieved, but large-scale and standardized production is hindered

Engineering Contradiction:
Core Design Contradiction:
ProductivityVSEase of manufacture

Solution Approach 1:

The patent uses chemically defined media with specific compositions (neural induction medium with N2 supplement and Non-Essential Amino Acid, retinal differentiation medium with B27 supplement) to control and standardize the differentiation process. This chemical parameter control enables reproducible, large-scale production of retinal progenitor cells with consistent quality, resolving the contradiction between productivity and ease of manufacture

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent divides the differentiation process into distinct stages (neural induction stage with embryoid body formation, followed by retinal differentiation stage with adherent monolayer culture), each with optimized media conditions. This segmented approach enables standardized, scalable production while maintaining high purity retinal cell output

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables the large-scale, standardized production of highly enriched retinal progenitor cells, improving the efficiency and purity of retinal cell production for drug development and regenerative therapies.

Implementation Method 1

The agent can be a WNT8B short hairpin interfering RNA (shRNA)

Methodology Applied
Scientific EffectRNA interference:

Data Source

PatentUS20200362301A1Efficient, scalable production of human retinal progenitors in vitro
Publication Date: 2020.11.19
  • US20200362301A1 patent drawing
  • US20200362301A1 patent drawing
  • US20200362301A1 patent drawing

AI summary

Provided herein are efficient, scalable methods for in vitro production of human retinal progenitor cells. In addition, provided herein are methods for isolating pure populations of in vitro produced human retinal progenitor cells as well as kits and compositions comprising such pure populations of human retinal progenitor cells.